Sage Therapeutics (SAGE) Competitors $7.48 +0.19 (+2.61%) Closing price 05/1/2025 04:00 PM EasternExtended Trading$7.39 -0.09 (-1.20%) As of 08:25 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SAGE vs. GMTX, BEAM, NAMS, KYMR, BLTE, BHC, JANX, AAPG, ARWR, and HRMYShould you be buying Sage Therapeutics stock or one of its competitors? The main competitors of Sage Therapeutics include Gemini Therapeutics (GMTX), Beam Therapeutics (BEAM), NewAmsterdam Pharma (NAMS), Kymera Therapeutics (KYMR), Belite Bio (BLTE), Bausch Health Companies (BHC), Janux Therapeutics (JANX), Ascentage Pharma Group International (AAPG), Arrowhead Pharmaceuticals (ARWR), and Harmony Biosciences (HRMY). These companies are all part of the "pharmaceutical products" industry. Sage Therapeutics vs. Gemini Therapeutics Beam Therapeutics NewAmsterdam Pharma Kymera Therapeutics Belite Bio Bausch Health Companies Janux Therapeutics Ascentage Pharma Group International Arrowhead Pharmaceuticals Harmony Biosciences Sage Therapeutics (NASDAQ:SAGE) and Gemini Therapeutics (NASDAQ:GMTX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, community ranking, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation. Do insiders and institutionals hold more shares of SAGE or GMTX? 99.2% of Sage Therapeutics shares are owned by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are owned by institutional investors. 5.5% of Sage Therapeutics shares are owned by company insiders. Comparatively, 12.9% of Gemini Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more volatility and risk, SAGE or GMTX? Sage Therapeutics has a beta of 0.48, suggesting that its share price is 52% less volatile than the S&P 500. Comparatively, Gemini Therapeutics has a beta of -0.12, suggesting that its share price is 112% less volatile than the S&P 500. Do analysts recommend SAGE or GMTX? Sage Therapeutics presently has a consensus target price of $8.81, suggesting a potential upside of 17.81%. Given Sage Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Sage Therapeutics is more favorable than Gemini Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sage Therapeutics 2 Sell rating(s) 15 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor SAGE or GMTX? In the previous week, Sage Therapeutics had 18 more articles in the media than Gemini Therapeutics. MarketBeat recorded 18 mentions for Sage Therapeutics and 0 mentions for Gemini Therapeutics. Sage Therapeutics' average media sentiment score of 0.23 beat Gemini Therapeutics' score of 0.00 indicating that Sage Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Sage Therapeutics Neutral Gemini Therapeutics Neutral Is SAGE or GMTX more profitable? Gemini Therapeutics has a net margin of 0.00% compared to Sage Therapeutics' net margin of -971.50%. Gemini Therapeutics' return on equity of -38.78% beat Sage Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Sage Therapeutics-971.50% -68.18% -60.84% Gemini Therapeutics N/A -38.78%-35.88% Which has higher valuation and earnings, SAGE or GMTX? Gemini Therapeutics has lower revenue, but higher earnings than Sage Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Sage Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSage Therapeutics$41.24M11.15-$400.67M-$6.59-1.14Gemini TherapeuticsN/AN/A-$71.87M-$1.00-49.42 Does the MarketBeat Community believe in SAGE or GMTX? Sage Therapeutics received 614 more outperform votes than Gemini Therapeutics when rated by MarketBeat users. Likewise, 65.06% of users gave Sage Therapeutics an outperform vote while only 63.33% of users gave Gemini Therapeutics an outperform vote. CompanyUnderperformOutperformSage TherapeuticsOutperform Votes63365.06% Underperform Votes34034.94% Gemini TherapeuticsOutperform Votes1963.33% Underperform Votes1136.67% SummarySage Therapeutics beats Gemini Therapeutics on 11 of the 17 factors compared between the two stocks. Get Sage Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SAGE vs. The Competition Export to ExcelMetricSage TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$459.88M$6.85B$5.54B$7.93BDividend YieldN/A2.97%5.09%4.22%P/E Ratio-1.147.3222.5518.54Price / Sales11.15241.43395.25103.29Price / CashN/A65.8538.1834.62Price / Book0.996.486.764.25Net Income-$400.67M$143.41M$3.22B$248.18M7 Day Performance-3.98%2.58%1.37%1.03%1 Month Performance-3.73%5.00%2.77%2.70%1 Year Performance-42.92%-3.72%15.59%4.05% Sage Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SAGESage Therapeutics3.7262 of 5 stars$7.48+2.6%$8.81+17.8%-43.7%$459.88M$41.24M-1.14690Earnings ReportAnalyst RevisionNews CoverageGMTXGemini TherapeuticsN/A$42.17+2.8%N/A+73.2%$1.83BN/A-42.1730BEAMBeam Therapeutics3.0896 of 5 stars$18.24+7.3%$49.45+171.1%-8.8%$1.82B$63.52M-10.36510Upcoming EarningsShort Interest ↑News CoverageHigh Trading VolumeNAMSNewAmsterdam Pharma3.1676 of 5 stars$16.26-0.5%$43.33+166.5%-8.8%$1.79B$45.56M-6.254Positive NewsKYMRKymera Therapeutics2.0009 of 5 stars$27.16+4.6%$56.36+107.5%-4.7%$1.76B$47.07M-11.61170Upcoming EarningsNews CoveragePositive NewsBLTEBelite Bio2.9701 of 5 stars$54.69-3.0%$96.67+76.8%+50.9%$1.74BN/A-49.2710News CoveragePositive NewsBHCBausch Health Companies4.1781 of 5 stars$4.72-7.5%$7.17+51.8%-39.5%$1.74B$9.63B-39.3319,900Analyst UpgradeJANXJanux Therapeutics3.0253 of 5 stars$29.30-1.3%$95.25+225.1%-44.9%$1.73B$10.59M-25.0430Upcoming EarningsNews CoveragePositive NewsGap DownAAPGAscentage Pharma Group InternationalN/A$19.12+2.1%N/AN/A$1.66B$980.65M0.00600ARWRArrowhead Pharmaceuticals3.5916 of 5 stars$12.08+7.5%$41.44+243.1%-39.4%$1.66B$2.50M-2.34400Positive NewsHRMYHarmony Biosciences4.822 of 5 stars$28.50+0.1%$53.33+87.1%-1.4%$1.63B$714.73M13.51200Upcoming EarningsAnalyst RevisionNews CoveragePositive News Related Companies and Tools Related Companies Gemini Therapeutics Competitors Beam Therapeutics Competitors NewAmsterdam Pharma Competitors Kymera Therapeutics Competitors Belite Bio Competitors Bausch Health Companies Competitors Janux Therapeutics Competitors Ascentage Pharma Group International Competitors Arrowhead Pharmaceuticals Competitors Harmony Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SAGE) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sage Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sage Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SAGE Stock Free SAGE Stock Alerts